07 Oct 2026, 15:25 IST
Anthem Biosciences Limited
HDFC Securities · ADD · target Rs 950
The report expects 23% YoY revenue growth led by the CRDMO business, naming it a strong performer.
From Pharma and Healthcare Q2FY27 Preview HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.